AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

AbbVie (ABBV) reported better-than-expected fourth-quarter results on Friday amid robust sales of Skyrizi and Rinvoq, ...

Below, find the full data for April’s 10 biggest pharma ad spenders, as compiled by iSpot.TV. 1. Skyrizi Movement: Up three spots What is it? AbbVie’s immunology drug Est. national TV ad spend ...